VSV-ZEBOV Overview

Reviewed: October 22, 2014

VSV-ZEBOV is an investigational Ebola vaccine currently being tested for safety and the ability to generate an immune response in healthy adults.

VSV-ZEBOV was developed by researchers at the Public Health Agency of Canada’s National Microbiology Laboratory. It has been licensed to NewLink Genetics Corp through its wholly owned subsidiary BioProtection Systems, both based in Ames, Iowa.

The vaccine is being tested as two intramuscular doses by the National Institute of Allergy and Infectious Diseases (NIAID), and as a single dose at the Walter Reed Army Institute of Research (WRAIR). The NIH Phase 1 clinical trial of the VSV-ZEBOV vaccine candidate will enroll 39 healthy adults aged 18 to 65 years.

Initial safety and immune response data on the VSV-ZEBOV vaccine are expected by the end of 2014.

Patient Ratings for

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?